about
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesDPP4 in DiabetesComparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonEmerging gliptins for type 2 diabetes.Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted ratsDipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand.The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Metformin + saxagliptin for type 2 diabetes.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Cardiovascular effects of gliptins.Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Efficacy and safety of Jentadueto® (linagliptin plus metformin).Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatmentCardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Novel DPP-4 inhibitors against diabetes.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.DPP-4 inhibitors: pharmacological differences and their clinical implications.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.Omarigliptin for the treatment of type 2 diabetes.
P2860
Q24628948-C51F0C24-8890-4A43-9609-ECE9C212E77EQ26797335-6643F5A7-4588-45F1-B837-E8B15F4FA249Q33785197-851C1322-C15D-4C84-8B74-A442625FE20CQ34347884-9D8C6FF9-E9CC-4E0B-995D-E7BB2CE44A36Q34353892-0BEFB74C-7B52-4CAF-AD15-F0DEFC368172Q34891146-7478760B-DD70-4F3E-9C53-396841D1B275Q35759370-18335568-F4B8-4731-8E1F-0306F3E10F6BQ35860311-C2A26844-A43A-4448-8270-C573988D0741Q36196649-EC23AA12-1D36-4B60-8F8A-0328272E4068Q36691245-BFD609EF-9E1E-4E83-B9AA-A68D71AB9C4BQ37195882-185FA318-D62D-420D-82F2-4F6EFA162731Q37284014-076BC104-DC22-4525-A7E6-453AB362D929Q37366826-19F90720-E5AD-495F-9451-4D4BA7FDC72CQ37590929-A1D516F0-E7A7-4BB3-AD01-A4811497FA33Q37722896-DDB17745-A2E5-4557-A8E9-5FB678431075Q37965618-1ECE3FEC-0878-46DB-9124-A6A2D47E4268Q37982112-301DAE36-459C-43D4-A1B6-5AE743C666F5Q38010243-A5FF6C3A-1166-45F7-B3A2-869A4CD2DEDAQ38012068-9FCA32B3-C2C0-4F92-A99F-ECCACBD50B92Q38072259-BAC62A07-AD0A-46C1-A370-36FD59365387Q38078436-D072F1D8-CEE0-483A-AF2B-B52FE266A3A9Q38082848-D1C46D37-8C5A-48C2-A6C5-3FE4E84B5397Q38086611-9AE26517-57A0-44C3-BC93-7238E37B17C8Q38101993-271B269D-F339-4080-9DF7-E1B9704A7840Q38108636-1D90324B-FD88-4FE5-A729-2C2258230D76Q38113092-70F3C025-512B-495F-9516-1BB0DE65FC1EQ38199526-D009FB5F-FE2E-4BB5-AB3E-1CAB965E995CQ38221278-489AE9C4-E016-4269-BDC7-39895BB5B7AFQ38236774-CE74167B-097E-4AEC-B392-EFA20B8337FFQ38244576-87119D96-5F1D-48FB-8DFA-B69FF179B45BQ38261573-B5DADB2C-2CBA-46A7-AE5C-B6279F5083E3Q38266290-4C7FF54C-CE48-4F67-B740-848CCF71CBEFQ38335751-14389E37-9ED4-44D8-AECE-48EAFF62839CQ38455771-17C19E2A-9F02-4935-9E10-20C8CAD9B4B9Q38546981-46AF7AB1-EF81-43A1-ACC5-581E2EBB3857Q38606170-8B124D69-2585-472C-93C7-E77B3A157192Q38663559-0D0AA9B7-7699-46D9-AD7E-C16A5AE2F75FQ38828606-E1709926-5231-4D95-9DFD-078200840F78Q38856808-3087091F-F0D6-4308-A442-C0F33AA4A8A2Q38884175-4EF54869-3954-4C44-864F-337BEE922807
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A review of gliptins in 2011.
@en
A review of gliptins in 2011.
@nl
type
label
A review of gliptins in 2011.
@en
A review of gliptins in 2011.
@nl
prefLabel
A review of gliptins in 2011.
@en
A review of gliptins in 2011.
@nl
P2860
P1476
A review of gliptins in 2011.
@en
P2093
André J Scheen
P2860
P356
10.1517/14656566.2012.642866
P407
P577
2012-01-01T00:00:00Z